By Colin Kellaher

 

Horizon Therapeutics tumbled in premarket trading Tuesday following a published report that U.S. regulators will move to block the $27.8 billion acquisition of the drugmaker by Amgen.

Bloomberg, citing a person familiar with the matter, late Monday reported that the Federal Trade Commission is expected to file a lawsuit Tuesday to block the deal on the grounds it would hamper innovation and slow the pace of drug development.

Amgen in December said it would pay $116.50 a share in cash for Horizon, marking the largest healthcare merger announced in 2022.

Amgen said it wasn't aware of any FTC decision on the deal, while Horizon deferred comment to Amgen, according to the Bloomberg report.

Horizon shares, which closed Monday at $112.25, were recently down nearly 17% at $93.49 in premarket trading, while Amgen shares edged up 0.6% to $235.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

May 16, 2023 06:14 ET (10:14 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Amgen.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Amgen.